Free tool
Diagnostics stocks
We cover 8 companies grouped under the Diagnostics theme. The median market value in the group is $3.87B. Across the group, the median move over the past trading day is −0.50%. Price change over the past year runs from −29.9% to +113.7% across the middle 80 percent of the group, with a median of +22.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
8 of 150 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −9.65% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% |
| BLLN | BillionToOne, Inc. | $4.54B | Mid cap | −11.68% |
| ADPT | Adaptive Biotechnologies Corporation | $4.18B | Mid cap | +101.70% |
| VCYT | Veracyte, Inc. Common Stock | $3.56B | Mid cap | +54.81% |
| GRAL | GRAIL, Inc. | $3.55B | Mid cap | +136.66% |
| WGS | GeneDx Holdings Corp. | $2.69B | Mid cap | −30.11% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.